Cardiac endothelium–myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Heart failure (HF) is an important global health problem with great socioeconomic burden. Outcomes remain sub-optimal. Endothelium-cardiomyocyte interactions play essential roles in cardiovascular homeostasis, and deranged endothelium-related signalling pathways have been implicated in the pathophysiology of HF. In particular, disturbances in nitric oxide (NO)-mediated pathway and neuregulin-mediated pathway have been shown to contribute to the development of HF. These signalling pathways hold the potential as pathophysiological targets for new HF therapies, and may aid in patient selection for future HF trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957 · cited 1×
“This trial has recently been completed and published; LCZ 696 resulted in a 16% reduction in allcause mortality, 20% reduction in cardiovascular mortality and 21% reduction in HF hospitalizations among chronic HFREF patients.(97) Although augmentation of the NP pathway by LCZ 696 may be expected to boost endothelial f…”
MethodA Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564 · cited 1×
“NO is then diverted to peroxynitrite by its interaction with superoxide.(27)”
BackgroundEffect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142404 · Cited by 2,400
O'Connor (2009) · doi:10.1001/jama.2009.454 · Cited by 2,173
Long-term trends in the incidence of and survival with heart failure
Levy, D., Kenchaiah, S., Larson, M. G., Benjamin, E. J., Kupka, M. J., Ho, K. K. L., Murabito, J. M., & Vasan, R. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020265 · Cited by 2,152
Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042934 · Cited by 1,773
Epidemiology and clinical course of heart failure with preserved ejection fraction
Lam, C. S. P., Donal, E., Kraigher-Krainer, E., & Vasan, R. S. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq121 · Cited by 709
Self-citationBrutsaert, D. L. (2003) · Physiological Reviews · doi:10.1152/physrev.00017.2002 · Cited by 697 · cited 1×
“Communication between these cell types in a network structure is crucial for cardiac development, autoregulation, and adaptation.(6,7) The concept that cell–cell communication in the heart is important for cardiac performance was formulated almost 30 years ago by Brutsaert et al.”
BackgroundSelf-citationSolomon, S. D., Dobson, J., Pocock, S., Skali, H., McMurray, J. J. V., Granger, C. B., Yusuf, S., Swedberg, K., Young, J. B., Michelson, E. L., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.696906 · Cited by 681
Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension
Schulz, E., Jansen, T., Wenzel, P., Daiber, A., & Münzel, T. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1989 · Cited by 430
Cited by
Pudil, R., Mueller, C., Čelutkienė, J., Henriksen, P. A., Lenihan, D., Dent, S., Barac, A., Stanway, S., Moslehi, J., Suter, T. M., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2017 · Cited by 357
Heart failure with preserved ejection fraction: from mechanisms to therapies
Lam, C. S. P., Voors, A. A., de Boer, R. A., Solomon, S. D., & van Veldhuisen, D. J. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy301 · Cited by 355
Self-citationVascular Toxicities of Cancer Therapies: The Old and the New – An Evolving Avenue
Herrmann, J., Yang, E. H., Iliescu, C. A., Cilingiroglu, M., Charitakis, K., Hakeem, A., Toutouzas, K., Leesar, M. A., Grines, C. L., & Marmagkiolis, K. (2016) · Circulation · doi:10.1161/circulationaha.115.018347 · Cited by 329
Gevaert, A. B., Shakeri, H., Leloup, A. J., Van Hove, C. E., De Meyer, G. R. Y., Vrints, C. J., Lemmens, K., & Van Craenenbroeck, E. M. (2017) · Circulation: Heart Failure · doi:10.1161/circheartfailure.116.003806 · Cited by 211
Cellular senescence links aging and diabetes in cardiovascular disease
Shakeri, H., Lemmens, K., Gevaert, A. B., De Meyer, G. R. Y., & Segers, V. F. M. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00287.2018 · Cited by 134
“HFpEF is the most common form of HF observed in the elderly (108).”
BackgroundSelf-citation
Metadata
- Authors
- Lim, S. L., Lam, C. S. P., Segers, V. F. M., Brutsaert, D. L., & De Keulenaer, G. W.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-23
- Volume
- 36
- Issue
- 31
- Pages
- 2050-2060
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2113439549
- Cited by
- 152
- References
- 15
- FWCI
- 11.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiac endothelium–myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. https://app.cochat.ai/papers/10.1093/eurheartj/ehv132
- The paper
- Lim, S. L., Lam, C. S. P., Segers, V. F. M., Brutsaert, D. L., & De Keulenaer, G. W. (2015). Cardiac endothelium–myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. European Heart Journal. https://doi.org/10.1093/eurheartj/ehv132
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.